Adial pharmaceuticals announces publication in leading peer-reviewed journal supporting the potential efficacy of ad04 as a precision medicine for the treatment of alcohol use disorder

Ad04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified by a companion diagnostic test (cdx) ad04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified by a companion diagnostic test (cdx)
ADIL Ratings Summary
ADIL Quant Ranking